**Medical Diagnostics:** 70%
**Biotechnology Products:** 20%
**Research and Development:** 10%

**Top 3 Markets:**
**China:** 45%
**USA:** 30%
**Europe:** 15%

Guangzhou Wondfo Biotech Co., Ltd generates the majority of its revenue from medical diagnostics, followed by biotechnology products and research and development. The Chinese market is the largest single market, followed by the USA and Europe. These markets are crucial for the company as they exhibit high demand for diagnostic solutions and biotechnological innovations.

**Production Sites:** Guangzhou, China

Guangzhou Wondfo Biotech Co., Ltd mainly produces its products in Guangzhou, China. The company has its main production facilities there, specializing in the manufacturing of diagnostic test kits and biotechnological products. Guangzhou serves as a strategic location due to its proximity to key supply chains and the availability of qualified personnel.

**Growth Strategy:**

1. **Research and Development:** Guangzhou Wondfo Biotech Co., Ltd continuously invests in research and development to develop innovative diagnostic solutions. This includes both improving existing products and introducing new technologies.

2. **International Expansion:** The company focuses on entering new markets outside of China, especially in Europe and North America, to strengthen its global presence.

3. **Partnerships and Collaborations:** Wondfo Biotech actively seeks strategic partnerships and collaborations with other companies and research institutions to leverage synergies and accelerate product development.

4. **Diversification of Product Portfolio:** The company continuously expands its product portfolio to address various diagnostic needs and hedge against market fluctuations.

This strategy aims to solidify Wondfo Biotech's market position and ensure long-term sustainable growth.

**Main raw materials:** Chemicals, biological reagents, plastic components
**Main importing countries:** USA, Germany, Japan

Guangzhou Wondfo Biotech Co., Ltd imports a variety of raw materials necessary for the production of their biotechnological products. This includes especially special chemicals and biological reagents needed for the development of diagnostic and test kits.

These materials are mainly sourced from the USA and Germany, as these countries are leading in the production of high-quality biotechnological materials. Plastic components needed for the production of test kits and other medical devices are often imported from Japan, known for its high-quality plastic products.

The reliance on international suppliers requires effective supply chain management to ensure production continuity and guarantee the quality of the end products.

**Market Share in In-Vitro Diagnostics:** Estimated at 10% (2026, China)

**R&D Investments:** 8% of revenue (2025)

**Product Innovations:** 5 new product launches (2025)

Guangzhou Wondfo Biotech Co., Ltd has established itself as one of the leading providers in the field of in-vitro diagnostics in China. The estimated market share of 10% demonstrates the company's strong position in a competitive market.

The company continuously invests in research and development, as highlighted by the 8% of revenue allocated to R&D. These investments enable Wondfo to regularly introduce innovative products to the market, as evidenced by the five new product launches in 2025.

Additionally, Wondfo benefits from strong brand awareness and a broad distribution network that covers both domestic and international markets. This gives the company a sustainable competitive advantage over smaller or less diversified competitors.

**Institutional Investor Share:** Estimated 25-30% (2026)
**Insider Buys/Sells:** No specific data available (2026)

The institutional investor share in Guangzhou Wondfo Biotech Co., Ltd is estimated to be around 25-30%. This estimate is based on typical holdings in the biotechnology industry in China, where institutional investors often hold significant stakes to benefit from growth potentials.

Current data on insider buys or sells are not available. Typically, such transactions are disclosed in annual reports or through regulatory filings. It is advisable to consult the latest company reports or stock exchange announcements to obtain accurate information.

**Market share of Guangzhou Wondfo Biotech Co., Ltd:** Estimated 5-7% (2026)

**Top competitors and their market shares:**
1. **Abbott Laboratories:** 15%
2. **Roche Diagnostics:** 12%
3. **Siemens Healthineers:** 10%
4. **Thermo Fisher Scientific:** 9%
5. **Danaher Corporation:** 8%
6. **Becton Dickinson:** 7%
7. **Guangzhou Wondfo Biotech Co., Ltd:** 5-7%
8. **Bio-Rad Laboratories:** 4%
9. **Qiagen:** 3%
10. **PerkinElmer:** 2%

Guangzhou Wondfo Biotech Co., Ltd has a moderate market share compared to industry leaders. The company's moat mainly lies in its specialization in rapid tests and point-of-care diagnostics, which represents a certain niche in the market.

However, larger companies like Abbott and Roche have more comprehensive product portfolios, stronger brand recognition, and greater financial resources, giving them a broader and deeper moat. These companies can gain competitive advantages through their global presence and their ability to invest in research and development.

Nevertheless, Wondfo Biotech can strengthen its position through innovations and tapping into new markets. The focus on cost-effective and efficient solutions could provide an advantage in certain markets, especially in regions with limited access to expensive diagnostic solutions.

**Revenue Growth:** 10% (2025)
**Research and Development Ratio:** 8% of revenue (2025)
**Market Share in the Diagnostics Sector:** 5% (2025)

Guangzhou Wondfo Biotech Co., Ltd achieved a revenue growth of 10% in 2025, indicating a continuous demand for their diagnostic solutions. The company invests 8% of its revenue in research and development, pointing to a strong focus on innovation and product development.

With a 5% market share in the diagnostics sector, Wondfo Biotech demonstrates a solid market presence that could be further strengthened through strategic partnerships and an expanded product range. The ongoing investments in research and development could also lead to long-term competitive advantages.

Overall, the financial and strategic positioning of the company suggests solid potential for future growth, making it an interesting investment opportunity. However, investors should also keep an eye on external factors such as regulatory changes and market developments.

**Dividend Yield:** 1.8% (2025, estimated)
**Dividend History:** Regular payouts since 2018

Guangzhou Wondfo Biotech Co., Ltd has pursued a consistent dividend policy in recent years. The dividend yield was estimated at 1.8% in 2025, which can be considered moderate compared to other companies in the biotechnology industry.

The company has been regularly paying dividends since 2018, indicating a certain reliability in its payout policy. The financial stability and continuous growth of the company support its ability to continue distributing dividends in the future.